Novo Nordisk A/SMorgan Stanley downgraded Novo Nordisk to Underweight on semaglutide loss-of-exclusivity concerns.
UBS upgraded Lockheed Martin to Buy from Neutral, arguing accelerating missile production, rising defense spending and growth beyond the F-35 franchise could drive earnings above Wall Street expectations. Analyst Gavin Parsons expects Lockheed revenue to grow at a compound annual rate of approximately 9% through 2028, with UBS projecting revenue of $81.05 billion in 2026, $88.48 billion in 2027 and $96.13 billion in 2028, the last about 6% above consensus, and adjusted earnings of $30.69 a share in 2026, $34.50 in 2027 and $39.34 in 2028, 12% above consensus. JPMorgan upgraded Meta Platforms to Overweight from Neutral with an $820 price target, implying a 25% increase from last close, citing upside from the launch of its AI assistant and frontier models. Morgan Stanley downgraded Novo Nordisk to Underweight from Equal-weight on semaglutide loss-of-exclusivity concerns, while Northland Securities upgraded Intel to Outperform from Market Perform with a $120 price target, and UBS cut NuScale Power to Sell from Neutral with a $6 price target, slashed from $10.
Novo Nordisk A/SMorgan Stanley downgraded Novo Nordisk to Underweight on semaglutide loss-of-exclusivity concerns.
Novartis AG
Lockheed Martin CorporationUBS upgraded Lockheed Martin to Buy, projecting earnings and revenue above consensus.
Meta Platforms Inc.JPMorgan upgraded Meta to Overweight with an $820 price target.
Intel CorporationNorthland Securities upgraded Intel to Outperform with a $120 price target.
Nuscale Power CorpUBS cut NuScale Power to Sell with a price target slashed to $6 from $10.
Dell Technologies Inc
Peloton Interactive Inc
Tesla Inc